Senate Hearings Probe FDA Authority On Drug Label Changes, Safety Trials
This article was originally published in The Tan Sheet
Executive Summary
Giving FDA the authority to require changes to drug labeling could help the agency get drug safety information to the public more quickly, FDA Office of New Drugs Deputy Director Sandra Kweder told the Senate Health Committee March 1